Loading data
MAMANasdaq
| Unit: USD | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 171.71 m USD | 123.33 m USD | 103.28 m USD | 93.19 m USD | 47.08 m USD |
| Cost of revenue | 128.67 m USD | 92.8 m USD | 72.95 m USD | 73.77 m USD | 35.23 m USD |
| Gross profit | 43.05 m USD | 30.53 m USD | 30.33 m USD | 19.42 m USD | 11.85 m USD |
| Research and development expense | 288 k USD | 455 k USD | 414 k USD | 135 k USD | 120.69 k USD |
| Selling, general and administrative expense | 35.65 m USD | 25.2 m USD | 21.03 m USD | — | — |
| Operating profit | 7.11 m USD | 4.88 m USD | 8.89 m USD | 2.82 m USD | 82.77 k USD |
| Income tax expense | 1.57 m USD | 995 k USD | 2.01 m USD | 9 k USD | 296.47 k USD |
| Net income (reported basis) | 5.29 m USD | 3.71 m USD | 6.56 m USD | 2.3 m USD | -252 k USD |
| Net income attributable to common shareholders | 5.29 m USD | 3.71 m USD | 6.51 m USD | 2.27 m USD | -251.93 k USD |
| Basic earnings per share | 0.14 USD/share | 0.1 USD/share | 0.18 USD/share | 0.06 USD/share | -0.01 USD/share |
| Diluted earnings per share | 0.13 USD/share | 0.09 USD/share | 0.17 USD/share | 0.06 USD/share | -0.01 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.